Fibrotic lung disease and idiopathic pulmonary fibrosis
United Therapeutics Corp. supports clinical research in fibrotic lung disease, with particular attention to idiopathic pulmonary fibrosis and related interstitial lung disease presentations. Its studies focus on inhaled therapies used in chronic pulmonary fibrosis settings and on outcomes relevant to lung function and disease progression.
- Inhaled treprostinil
- Forced vital capacity
- Progressive pulmonary fibrosis
The sponsor’s trial portfolio includes multinational research across multiple sites in North America, Europe, and other active regions.
Pulmonary arterial hypertension
The company also funds studies in pulmonary arterial hypertension (PAH), where the therapeutic emphasis includes vascular-targeted treatment and long-term disease management. Research activity in this area addresses clinical worsening, symptom burden, and sustained treatment use in affected patients.
- Ralinepag
- Clinical worsening
- Pulmonary vascular disease
These studies involve collaborative work with a broad network of research sites and ongoing recruitment across several countries.
Long-term safety and tolerability research
A substantial part of the sponsor’s clinical program is devoted to extended evaluation of treatment safety and tolerability in chronic pulmonary disorders. This includes follow-up research for patients with IPF, PPF, and PAH, reflecting sustained interest in therapies used over long periods.
- Open-label extension studies
- Chronic respiratory disease
- Maintenance therapy
The sponsor’s funded trials span multiple therapeutic settings, linking fibrotic lung disease management with vascular lung disease care.
